12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Company News  |  Other News

Cytori gene/cell therapy news

The U.S. Court of Appeals for the District of Colombia upheld a 2009 FDA decision that two devices from Cytori will require approval through the PMA pathway rather than a 510(k) application. Cytori was seeking approval of its Celution 700 and StemSource 900 tissue processing systems for use in banking and research as Class 2 medical devices. The court concluded that...

Read the full 281 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >